Abstract | BACKGROUND: METHODS: Twenty-one patients with moderate to severe SHPT were included in a random 2 x 2 crossover trial with the two vitamin D analogs (12 weeks for each treatment). The primary endpoint measure was a decrease in serum intact PTH (iPTH) level, and the secondary outcome measures included changes in serum calcium (Ca), phosphate (P), and metabolic bone marker levels. RESULTS: CONCLUSION: The present study showed that oral falecalcitriol treatment is effective for PTH suppression, and Ca and P metabolism in hemodialysis patients with moderate to severe SHPT, as well as intravenous calcitriol administration.
|
Authors | H Ito, H Ogata, M Yamamoto, K Takahashi, K Shishido, J Takahashi, S Taguchi, E Kinugasa |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 71
Issue 6
Pg. 660-8
(Jun 2009)
ISSN: 0301-0430 [Print] Germany |
PMID | 19473635
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Biomarkers
- Bone Density Conservation Agents
- Collagen Type I
- Parathyroid Hormone
- Peptides
- collagen type I trimeric cross-linked peptide
- Osteocalcin
- Phosphorus
- Alkaline Phosphatase
- Calcitriol
- 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3
- Calcium
|
Topics |
- Administration, Oral
- Alkaline Phosphatase
(blood)
- Biomarkers
(blood)
- Bone Density Conservation Agents
(administration & dosage)
- Bone and Bones
(drug effects, metabolism)
- Calcitriol
(administration & dosage, analogs & derivatives)
- Calcium
(blood)
- Collagen Type I
(blood, drug effects)
- Cross-Over Studies
- Female
- Humans
- Hyperparathyroidism, Secondary
(drug therapy, etiology)
- Injections, Intravenous
- Kidney Failure, Chronic
(therapy)
- Male
- Middle Aged
- Osteocalcin
(blood, drug effects)
- Parathyroid Hormone
(blood)
- Peptides
(blood, drug effects)
- Phosphorus
(blood)
- Renal Dialysis
(adverse effects)
- Treatment Outcome
|